COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Protocol No
ALLIANCE-A171901
Principal Investigator
Jonathan Thompson
Phase
II
Summary
This study is being done to answer the following question: What are the side effects of MK-3475 (pembrolizumab) in patients who are 70 years of age or older? We are doing this study because we want to find out if patients aged 70 years or older have different side effects than younger patients from treatment with the usual approach for non-small cell lung cancer. The usual approach is defined as care most people get for non-small cell lung cancer. You will be given usual care if you participate in this study.
Description
Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer
Participating Institutions
Drexel Town Center
Froedtert West Bend Hospital
Froedtert Menomonee Falls Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category